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Introduction
The estimated annual incidence of nephrotic syndrome in healthy children is 2 to 7 new cases per 100,000 children younger than 18 years of age, making it a relatively common major disease in pediatrics. The peak age of onset occurs at 2 to 3 years except for the rare, congenital type of nephrosis. Approximately 50% of affected children are ages 1 to 4 years; 75% are younger than age 10 years. In addition, even the most benign form of the nephrotic syndrome is, by nature, a recurrent disorder, so each new-onset case likely will continue to manifest disease for some time. Nephrotic syndrome is one of the most frequent reasons for referral to a pediatric nephrologist for evaluation, although its insidious onset frequently causes delay in diagnosis.
Careful examination of the anatomy of a nephron permits characterization of the glomerular basement membrane as the barrier between the circulation and the external environment. Thus, the glomerular membrane, which permits passage in an adult of approximately 180 L/d of fluid, is the final determinant of how much of the solute originally contained in this volume enters the tubular lumen. The normal glomerular membrane is remarkably selective for protein compared with other solutes (Table 1) . Once this selectivity is lost, the ensuing proteinuria defines not only the diagnosis of nephrotic syndrome, but many pathophysiologic consequences as well. It is the purpose of this article to discuss the definition, causes, pathophysiologic consequences, and management of nephrotic syndrome. The emphasis is on the idiopathic form, which most often occurs in children as minimal-change nephrotic syndrome; other types of the nephrotic syndrome are mentioned briefly.
Definition
As anticipated from the name, the composite of clinical findings can be found either alone or in association with a number of systemic disorders, including toxicities. The sine qua non of the diagnosis of nephrotic syndrome is the presence of urinary protein, with the albumin disproportionately greater than the globulin, deriving from a loss of glomerular membrane selectivity. In the pediatric age group, urinary protein loss of 50 mg/kg per 24 hours or greater is a firm diagnostic criterion. It is imperative to recognize the distinctive origin of the proteinuria in the glomerulus rather than the tubule; nephrotic syndrome may be seen as exclusively glomerular in origin without any associated tubular dysfunction. Additionally, as a syndrome, the clinical picture may be either primary or secondary, and underlying causes must be excluded.
Clinical Diagnostic Criteria
The diagnostic criteria are: 1) generalized edema; 2) hypoproteinemia (Ͻ2 g/dL [20 g/L]), with disproportionately low albumin in relation to globulin; 3) urine protein (mg/dL) to urine creatinine (mg/dL) ratio in excess of 2 in a first morning void or a 24-hour urine protein that exceeds 50 mg/kg body weight; and 4) hypercholesterolemia (Ͼ200 mg/dL [5.17 mmol/L]).
The reduced serum albumin, which can fall to as low as 0.5 g/dL (5 g/L), causes a marked reduction in plasma oncotic pressure. Consequently, circulatory volume is lost to the interstitial spaces, resulting in generalized edema. Often, the initial swelling is observed as facial (especially periorbital) and pretibial edema, with prominent swelling of the scrotum or labia also seen. An additional consequence of the lowered oncotic pressure is reduced perfusion of the splanchnic capillary bed, which can cause abdominal pain. Pleural effusions may form, and frank pulmonary edema also may occur, with either or both resulting in tachypnea and chest pain.
Levels of serum cholesterol, triglyceride, and lipoprotein cholesterol are consistently elevated. The mechanism(s) underlying these changes are not understood completely, in part due to the complexity of lipid transport and the difficulties inherent in human clinical studies. Increases in very-low density and low-density lipoprotein (VLDL and LDL, respectively) cholesterol are characteristic findings. VLDL-cholesterol is increased as a consequence of decreased hepatic catabolism, thus increasing circulating triglyceride and cholesterol. LDL-cholesterol is increased due to an enhanced synthetic rate. What remains to be elucidated is the cause for these disturbances in hepatic lipid metabolism.
Primary nephrotic syndrome may occur at any age, from the neonate to the adult. The neonatal or congenital nephrotic syndrome, also called Finnish congenital nephrosis, is clearly defined as a genetic mutation in the nephrin gene and has been mapped to chromosome 19q13.1. Nephrin is a glomerular basement membrane protein that participates in formation of anionic-rich sites, causing electrochemical repulsion of plasma proteins. The mutation also has been reported in a Mennonite group in Pennsylvania who have no Finnish heritage and is believed to have arisen independent of the Finnish type. Primary childhood nephrotic syndrome rarely appears before 18 months to 2 years of age and peaks in incidence at about 3 years of age.
Laboratory Findings
The primary laboratory feature of the nephrotic syndrome is a marked proteinuria, in excess of 50 mg/kg per 24 hours (Table 2 ). The excreted protein is predominantly albumin, although immunoglobulins (Igs) also are lost. In uncomplicated cases of idiopathic nephrotic syndrome, it is unusual to see gross hematuria in the presence of proteinuria, although microscopic hematuria occurs in a sizeable proportion of cases. For patients who have gross hematuria and proteinuria, IgA nephropathy always must be a diagnostic consideration.
In the presence of clinical edema, measurement of serum protein will yield low values; the serum albumin is likely to be 2.0 g/dL (20 g/L) or lower. Albumin concentrations as low as 0.5 g/100 mL can be seen, and the albumin/globulin ratio is commonly less than 1.0. Concomitantly, and directly related to the reduced serum protein, hypocalcemia is found frequently, as reflected in reduced total and ionized fractions. However, hypocalcemia rarely is manifested clinically. Of much greater significance than hypocalcemia to patients who have nephrotic syndrome is the increased concentrations of coagulation factors, especially those of high molecular weight. Thrombin also is increased, while fibrinolytic activity and circulating quantities of platelet adhesion inhibitors are decreased. As a consequence of these changes, as well as the intravascular hypovolemia, affected patients are at greatly increased risk of thrombosis. In addition, IgG in plasma is reduced, which in combination with large steroid doses, may predispose to infection.
Children who become oliguric from diminished intravascular volume have a tendency to develop hyperkalemia. The use of diuretics may complicate the electrolyte disturbances further, necessitating close monitoring of serum electrolyte levels during treatment.
The Need for a Renal Biopsy
In the acute stage of childhood nephrotic syndrome, especially during the initial episode, renal biopsy usually is unnecessary. The key indications for biopsy in any renal disorder are the need to make a specific diagnosis for therapeutic reasons or to provide a prognosis. The treatment of initial-onset nephrotic syndrome is the same, irrespective of cause, and the need for determining a prognosis never can outweigh the risks of thrombosis, bleeding, and infection due to a biopsy in the acute stage of the disorder.
The subsequent disease course in a patient can help to determine the timing of a renal biopsy. In an uncomplicated case in which proteinuria clears within a few weeks in response to orally administered corticosteroids and normal renal function, the diagnosis is presumed to be minimal-change nephrotic syndrome. If there is no significant proteinuria between relapses that continue to respond promptly to corticosteroids, this diagnosis is strengthened. If the child is younger than 10 years of age at the initial presentation, no renal biopsy need be considered. At age 10 years or older, the increasing risk of underlying primary disease compels the need to obtain a biopsy for histologic diagnosis. In such cases, renal biopsy can be deferred until the child is stable and the family's anxieties over the immediate medical problems have dissipated.
In contrast, when there is poor or no response of the initial episode after 4 to 6 weeks of standard treatment (defined as steroid-resistance disease), biopsy should be considered as soon as the patient is medically stable. In such cases, the biopsy is essential to distinguish the nature and severity of the glomerular process, which may be primary or secondary (Table 3) . It should be clear from the plethora of types and causes of glomerular nephropathy that treatments and prognoses vary considerably, making specific diagnosis imperative. Because proteinuria and microscopic hematuria are injury responses of the glomerulus, the need for clarification through renal biopsy is plain. The underlying pathology (Figs. 1 to 5) varies with age; the incidence is summarized in Table 4 . The indications for initial kidney biopsies in the nephrotic syndrome are summarized in Table  5 .
Beyond the issue of renal biopsy for initial diagnosis, there are circumstances in which a subsequent biopsy may be considered. Glomerular injury may evolve over time such that the clinical findings (eg, increasing proteinuria, development of chronic renal insufficiency) change significantly. Such cases may represent progression of a disease that initially was diagnosed as minimalchange nephrosis by biopsy or progressive injury to the kidney by an underlying disease such as lupus nephropathy. In these situations, a second renal biopsy should be considered for evaluation of progressive renal disease.
Technological developments in ultrasonography have reduced significantly the risk associated with percutaneous renal biopsy in children. Moreover, the improvements in electron microscopy equipment and technique, coupled with decades of observation, have enhanced the ability of the histopathologist to interpret the specimen accurately. Nonetheless, a renal biopsy is not always essential to good medical care, and its use should be viewed judiciously in all patients.
Treatment
The treatment of primary childhood nephrotic syndrome is supportive and will be determined largely by the patient's clinical status. Boys can experience scrotal edema, which may cause testicular torsion. Other children may become short of breath due to pulmonary edema; still others may become oliguric and develop a functional azotemia. The latter is due to reduced circulating volume in the vascular space that results in temporary renal insufficiency. Any of these presentations, alone or in combination, demands immediate attention to symptomatic treatment.
Treatment of Acute-onset Disease
The unifying factor in this disease is depleted blood volume as a consequence of low oncotic pressure. Therefore, treatment should be directed at returning fluid to (Table 6 ). The intuitive solution to the diminished oncotic pressure is to restore serum albumin concentration to better than 2 g/dL (20 g/L) by intravenous infusion. However, the effectiveness of this measure is reduced considerably because of the hypoalbuminemia resulting from glomerular leakage of serum protein. The degree of urinary loss can be illustrated by the hepatic rate of albumin synthesis, which in adults can be as high as 12 to 14 g/d. If a patient becomes hypoalbuminemic at such endogenous rates of replacement, it is apparent that replacement by infusion can only be a temporary remedy. Nonetheless, for a patient who has pulmonary edema or renal shutdown, intravenous albumin (1 g/kg of a 25% solution) can be very effective in mobilizing fluid into the vascular space. The rate of increase in oncotic pressure is directly proportional to the rate of expansion of intravascular volume. Thus, too rapid an infusion will place the child at risk for congestive heart failure. Accordingly, intravenous albumin should be infused continuously over 8 to 12 hours under close supervision.
As intravascular space expands, renal perfusion improves, and with it, the opportunity to reduce accumulated fluid volume is enhanced. Administration of a diuretic is the obvious means by which to maximize this opportunity. Keeping in mind that a normal or low serum sodium concentration is likely to represent the result of a dilutional effect, the choice of diuretic should be directed at sodium as well as at water excretion. An ideal choice is a loop diuretic such as furosemide, which can be administered at a dose of 1 to 2 mg/kg intravenously and acts within 15 minutes. Furosemide-induced inhibition of active chloride reabsorption in the ascending loop of Henle results in urinary excretion of sodium, chloride, and water. A portion of the calculated furosemide dose can be administered during the albumin infusion or it all can be administered at the end of the Debate continues over the true benefit of albumin infusion, and no resolution is in sight. Nonetheless, it is difficult to argue against its use in the clinical settings of pleural effusion, pulmonary edema, or impending renal shutdown due to depleted intravascular volume.
The child should be started on oral corticosteroid therapy after a negative tuberculosis skin test result has been determined. Prednisone is the usual drug of choice, and the recommended maximum daily dose is 60 mg/m 2 at HAM-TMC Library on November 13, 2008 http://pedsinreview.aappublications.org Downloaded from or 2 mg/kg. The daily dose should be maintained for 4 to 6 weeks. Opinion varies regarding this recommendation, ranging from daily treatment administered just long enough to achieve remission to 6 weeks of daily treatment. Following remission, the dose should be kept constant while changing to an alternate-day schedule for an additional 6 weeks. A measurable decrease in urine protein excretion should not be anticipated for at least 7 to 10 days following the initiation of treatment, so the patient's degree of proteinuria should not determine the length of a hospital stay. Children who have mild-to-moderate edema, no pulmonary edema, and a good diuretic response generally require a hospital stay of no more than 2 to 3 days.
Fluid balance must be monitored closely in the early stages of treatment. Optimal nutrition, including high-quality protein in amounts required for growth, is essential because the demand for albumin replacement is increased. The child should follow a "no salt-added" diet, with maintenance sodium provided for replacement during diuresis. Daily weights are key to assessing the therapeutic progress. Other adjunctive treatment, such as anticoagulation therapy, should be used judiciously. If laboratory evidence is sufficient to consider coagulopathy, heparin may be used at a dose of 50 U/kg intravenously and 100 U/kg every 4 hours intravenously for maintenance.
Using the treatment outlined previously, 85% to 90% of children who have an initial onset of minimal-change nephrotic syndrome will achieve satisfactory therapeutic responses. For the few who do not experience a remission with absence of proteinuria within the first 2 to 3 months after onset, alternative therapies are available.
Chronic and Outpatient Treatment
For most children who have minimal-change nephrotic syndrome, the proteinuria will clear by the third week of oral prednisone treatment. This is a sufficient diagnostic criterion to confirm the diagnosis. The small percentage of children who are not completely free of proteinuria for at least 3 to 5 days or those whose proteinuria continues beyond 3 months are classified as frequent relapsing/ steroid-dependent or steroid-resistant patients, respectively. For many such patients, different steroid-based strategies or alternative treatments may be required (Table 7) .
Long-term maintenance on daily or alternate-day low-dose oral prednisone may be appropriate for patients who experience frequent relapses. Many children remain in long-term remission on such a regimen with few, if any, adverse effects. If the child can be kept in remission with relatively low steroid doses in the absence of adverse effects, this approach is optimal because it is the least harmful of the available choices. On the other hand, when high steroid doses are required for maintenance or when steroid-related adverse effects supervene, alternative medications are required because the child clearly has a steroid-resistant nephrotic syndrome.
Among the alternative medications are several immunosuppressive agents as well as an antihelminthic and certain nonsteroidal medications (Table 7) . The usual choices are cyclophosphamide and chlorambucil, each of which can be used to achieve an initial remission or to render the steroid-resistant child relatively more steroidresponsive. The recommended dose of each is listed in Table 7 . However, each is associated with a rather impressive list of systemic and specific organ toxicities, which is the key reason for their general use as alternative modalities. Either may be used over 2 to 3 months to induce a complete remission, but after completion of treatment, more than 50% of patients experience a relapse, usually within 2 years. Moreover, in many such relapses, the degree of steroid resistance is greater than prior to the use of the immunosuppressive agent. Cyclosporine also has been used for induction of a remission in steroid-resistant patients. Although effective in this respect, relapse occurs on drug discontinuation, unlike chlorambucil and cyclophosphamide. Thus, the primary advantage of all three drugs in steroid-resistant nephrotic syndrome is to permit use of smaller doses of steroids, thereby minimizing steroid-related adverse effects. Recently, the results of a clinical trial have been published for a new agent for induction of remission in relapsing nephrotic syndrome. The double-blind, placebo-controlled, multicenter trial examined the immunosuppressive drug mizoribine (Table 7) . The agent decreased the relapse rate and prolonged remission in children 10 years of age and older, with relatively few adverse effects. However, additional experience with this drug must be acquired before it can be considered for routine use. A clinical trial of the drug mycophenolate mofetil in treatment of diffuse proliferative lupus nephritis documented equivalent efficacy to cyclophosphamide with far fewer adverse effects. Its use in treatment of idiopathic nephrotic syndrome has not yet been reported, nor can its safety for use in children be assumed at this time.
Nonsteroidal agents (Table 7) , such as antiinflammatory drugs and angiotensin-converting enzyme inhibitors, may be of limited use as alternative therapeutic agents in those very few patients who are refractory to steroids. A combination of captopril and indomethacin has been reported as effective for treatment of early-onset (within the first several months of life) nephrotic syndrome. The mechanism of action is related to effects on renal blood flow and glomerular filtration rather than to immunosuppression, so the decrease in proteinuria achieved is not a result of alterations in the basic disease mechanism. Secondary effects of altered renal perfusion may predispose the already intravascularly depleted patient to acute renal failure, requiring careful monitoring when using these agents.
Because minimal-change nephrosis occurs most commonly in young children, there may be problems related to routine childhood immunizations. It is clear that no child should receive immunizations during treatment with high-dose steroids to gain remission or with immunosuppressive agents to address frequent relapses. However, because relapses often are related to viral illness, use of live virus vaccines during remissions are viewed with disfavor by some nephrologists. A recent study suggested no unanimity of opinion among pediatric nephrologists with respect to immunization practices for children who have nephrotic syndrome. Because affected patients are prone to pneumococcal infection, the American Academy of Pediatrics recommends use of the polyvalent vaccine (Pneumovax ) in children older than 2 years and prophylactic penicillin in those younger than 2 years.
Complications
Because minimal-change nephrotic syndrome is a selflimited disease in the majority of affected children, a clear distinction should be made between complications of the disease and those that more likely are related to the treatment. For example, a patient treated with high-dose prednisone is at greater risk for the development of many steroid-related disorders (eg, gastrointestinal ulcer, insulin resistance), which are not among the known complications of nephrotic syndrome (Table 8) .
One true complication of nephrotic syndrome is the tendency to develop infections (eg, peritonitis, cellulitis, sepsis). A major source of morbidity from infection in those who have nephrosis is peritonitis, which results from multiple abnormalities of the humoral antibody system. IgG antibody is lost in the urine, and complement activation is impaired by concomitant loss of factor B. Other events in the bowel may contribute to the tendency. Marked intravascular depletion causes diminished splanchnic blood flow and hypoxia, and a marked tendency to thrombosis may cause microinfarctions, lowering resistance of the bowel wall to bacterial passage. The organisms causing peritonitis include Streptococcus pneumoniae and Escherichia coli. Peritonitis is a major contributor to the 1% to 2% mortality in nephrotic syndrome and always should be considered in an affected patient who complains of abdominal pain. Abdominal paracentesis then should be performed. Bacterial invasion of the skin, usually by gram-positive organisms, appears as erysipelas, with sharply demarcated borders and associated lymphangitis.
The second major contributor to both mortality and morbidity in this disease is thromboembolism. There is a real risk of thrombosis in children experiencing an initial or recurrent episode of nephrotic syndrome. However, there is no justifiable reason to use anticoagulant therapy during remission because coagulopathy is a result of serum protein abnormalities introduced by renal protein wasting. In those very few outpatients who have refractory nephrosis, it may be worthwhile to consider chronic, low-dose anticoagulants. In all children experiencing an acute nephrotic episode, platelets are hyperaggregable. There is limited experience with dipyridamole, an agent that interferes with platelet aggregation, in this disease. Several factors converge to create a marked propensity for thrombus formation: increased platelet aggregation, increased fibrinogen concentration combined with urinary loss of antithrombin-III, increased blood viscosity, and decreased blood flow. Venous thrombosis predominates and can be found in deep vessels of the extremities, the renal vein, the pulmonary venous system, and the cerebral cortical system. Arterial occlusion is uncommon but has been associated with serious morbidity and even mortality. The potential for this particular complication should be carefully considered. Initial coagulation studies should be obtained on admission for treatment and anticoagulants used judiciously only when appropriate, based on the results.
The well-known hyperlipidemia associated with the nephrotic syndrome generally is not a source of clinical complications. Because most cases of minimal-change nephrosis are steroid-responsive, the hyperlipidemia generally is reversed within 4 to 6 weeks. However, in more chronic situations, it may become necessary to institute long-term dietary changes and, possibly, drug therapy.
Finally, growth often is impaired in the nephrotic syndrome. Clinical evidence suggests that the proteinuria may cause the marked stunting that is seen in congenital nephrosis. There may be losses of insulin-like growth factor (IGF)-binding protein, which could account for the depressed serum concentrations of IGF-I and IGF-II. Moreover, experimental evidence shows that IGFreceptor mRNA also is depressed. Because high doses of steroids also may impair growth, the effects of loss of intrinsic growth factors may be compounded by treatment. Finally, there is experimental evidence that administration of growth hormone to nephrotic rats worsens the severity of glomerulosclerosis. Much more study is required before use of recombinant human growth hormone becomes accepted treatment for growth disturbances in the nephrotic syndrome.
Prognosis
Mortality in minimal-change nephrotic syndrome is approximately 2%, with the majority of deaths due to peritonitis or thrombus, which may occur even under the best of treatment circumstances. These complications may occur in the acute phase of the disease, despite steroid responsiveness. Thus, although those who have congenital nephrosis are steroid-and immunosuppressant-resistant, mortality cannot be attributed to this form of the disorder alone. Nonetheless, IgG ϭ circulating immune gamma-globulin, IGF ϭ insulin-like growth factor, mRNA ϭ messenger RNA, rhGH ϭ recombinant human growth hormone renal disease nephrotic syndrome the rare patient who has congenital nephrotic syndrome represents a considerable therapeutic challenge, requiring constant attention to serum protein and fluid levels, monitoring of nutrition balance, and treatment of infection.
Of the remaining 98% of children who have minimalchange nephrosis, most are steroid-responsive and can be expected to return eventually to a normal state. By its nature, minimal-change nephrotic syndrome results in relapses; about two thirds of patients experience at least a single relapse, with another third possibly developing a protracted series of such relapses over many years. It is important to note that a child who is steroid-responsive at the initial presentation may relapse more than once before the disease ultimately disappears. Many clinical observers have reported an inverse relationship between the age of presentation and the length of the disease course. In general, most patients who have minimalchange disease do very well, ultimately become diseasefree, and have a normal life expectancy.
Most patients who have presumptive minimal-change nephrotic syndrome and become steroid-resistant later in the disease course have developed focal segmental glomerular sclerosis (FSGS) (Fig. 3) , which arguably is a later evolutionary stage of minimal-change disease to which some patients progress. The early clinical signs of FSGS are indistinguishable from minimal-change disease, but at least one third of patients whose disease evolves to FSGS progress to end-stage renal failure within 5 years. In general, those who have more severe nephrotic syndrome, with hypertension and active urine sediments, and those who are older than 12 years of age at onset are the most likely to develop FSGS. However, it is not clear whether the severity of disease is a true prognostic marker, rather than a factor that may be more likely to result in intrinsic renal damage.
The hypovolemia and decreased renal perfusion intrinsic to the nephrotic syndrome render the affected individual susceptible to acute renal failure during an acute episode. Acute renal failure is defined as a sudden loss of renal function that is easily and physiologically reversible if no significant cellular injury has occurred due to hypoxia. In the latter event, there is a high risk of acute tubular necrosis, which greatly increases the risk of irreversible damage to the kidneys. If such damage occurs, chronic renal insufficiency supervenes and reverses the relatively good prognosis of minimal-change nephrosis.
For those patients whose chronic renal insufficiency progresses to end-stage renal disease, there is always the promise of hemodialysis/renal transplantation. However, for patients who have FSGS, there is a 25% risk of recurrence of FSGS in the transplanted kidney, and nephrotic syndrome occasionally occurs after renal transplantation independent of whether it was previously present.
The long-term prognosis for all categories of nephrotic syndrome (Table 4) in patients younger than 19 years of age is as follows: 20% will continue in remission, 50% will have one or two relapses in any 5-year follow-up period, and the remaining 30% will develop either frequent-relapsing nephrosis or steroid-resistant nephrosis. The third category of patients requires diagnostic renal biopsy. If minimal-change disease is confirmed, there is a 50% chance for these children to go into remission after a course of combined cytotoxic and prednisone therapy.
Recovery is deemed permanent if the child is symptom-free and off medications for more than 2 years.
